Combined Therapy of Chemotherapy and Radiofrequency Ablation for Pancreatic Cancer Patients With Metachronous Hepatic Metastatic Lesions After Radical Pancreatic Resection

Overview

Journal Cancer Control

Specialty Oncology

Date 2024 Aug 16

PMID 39150275

Authors

L T Wang

J Yang

J Wu

W J Lu

Affiliations

Soon will be listed here.

Abstract

Purpose: Hepatic metastasis frequently occurs in patients who have undergone radical pancreatic resection for pancreatic cancer. Besides chemotherapy, various local treatment approaches targeting hepatic lesions have been explored. However, research on radiofrequency ablation (RFA) as a localized therapy for hepatic metastasis is limited. Therefore, we conducted this retrospective study to provide clinical evidence.

Methods: This is a single-center, retrospective, cohort study. After radical pancreaticoduodenectomy, 32 patients developed metachronous hepatic metastasis with fewer than 3 lesions, the largest of which was less than 3 cm in diameter. These patients underwent combined treatment with chemotherapy and RFA. After 8 weeks of chemotherapy, patients received RFA for hepatic lesions. Additional chemotherapy was administered, and the patients' tumor status and survival were monitored. The primary endpoint of this study was overall survival (OS). Factors affecting OS were analyzed using the Cox risk model.

Results: Among the 32 patients, the mean OS was 28.4 months. Univariate and multivariate Cox regression analysis revealed that the time (in months) of liver metastasis (HR = 0.04, 95% CI: 0.01 to 0.19; < 0.001), the number of liver metastases (HR = 7.08, 95% CI: 1.85 to 27.08, = 0.004), and PD (progressive disease) response to the second round of chemotherapy (HR = 29.50, 95% CI: 1.46 to 597.27; = 0.027) were independent predictors of poorer survival.

Conclusion: Combined therapy with RFA and chemotherapy is safe in patients with hepatic metastasis after radical pancreaticoduodenectomy. Early recurrence (≤12 months), three liver metastatic lesions, and a poor response to the second round of chemotherapy were associated with poor survival.

References

Iida T, Nakabayashi Y, Okui N, Shiba H, Otsuka M, Yanaga K . Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. Anticancer Res. 2014; 34(5):2417-20. View

Zhu Z, Huang J, Liao M, Zeng Y . Treatment strategy for hepatocellular carcinoma in China: radiofrequency ablation versus liver resection. Jpn J Clin Oncol. 2016; 46(12):1075-1080. DOI: 10.1093/jjco/hyw134. View

Masuda T, Margonis G, Andreatos N, Wang J, Warner S, Mirza M . Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors. Anticancer Res. 2018; 38(11):6353-6360. DOI: 10.21873/anticanres.12993. View

Houg D, Bijlsma M . The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018; 17(1):95. PMC: 6003100. DOI: 10.1186/s12943-018-0842-9. View

Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A . Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2016; 43(2):358-363. DOI: 10.1016/j.ejso.2016.10.023. View

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I . Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388(10041):248-57. DOI: 10.1016/S0140-6736(16)30583-9. View

Tajima H, Kitagawa H, Tsukada T, Okamoto K, Nakanuma S, Sakai S . Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Mol Clin Oncol. 2014; 1(5):869-874. PMC: 3916203. DOI: 10.3892/mco.2013.152. View

Arnoletti J, Fanaian N, Reza J, Sause R, Almodovar A, Srivastava M . Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. Cancer Biol Ther. 2018; 19(10):887-897. PMC: 6300340. DOI: 10.1080/15384047.2018.1480292. View

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

10.

Kamarajah S, Burns W, Frankel T, Cho C, Nathan H . Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. Ann Surg Oncol. 2017; 24(7):2023-2030. DOI: 10.1245/s10434-017-5810-x. View

11.

Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T . Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol. 2018; 2018:4756147. PMC: 6008833. DOI: 10.1155/2018/4756147. View

12.

Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S . Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Pancreatology. 2014; 14(6):524-9. DOI: 10.1016/j.pan.2014.09.006. View

13.

Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B . Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (Basel). 2019; 11(11). PMC: 6895979. DOI: 10.3390/cancers11111659. View

14.

Lu F, Poruk K, Weiss M . Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015; 27(4):358-67. PMC: 4560742. DOI: 10.3978/j.issn.1000-9604.2015.05.02. View

15.

Groot V, Gemenetzis G, Blair A, Rivero-Soto R, Yu J, Javed A . Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg. 2019; 269(6):1154-1162. PMC: 6191366. DOI: 10.1097/SLA.0000000000002734. View

16.

Jong M, Tsai S, Cameron J, Wolfgang C, Hirose K, Van Vledder M . Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010; 102(3):256-63. DOI: 10.1002/jso.21610. View

17.

Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q . PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020; 19(1):49. PMC: 7053129. DOI: 10.1186/s12943-020-01167-9. View

18.

Kubo M, Yamada D, Eguchi H, Iwagami Y, Noda T, Asaoka T . [A Case of Resection for Lymph Node Recurrence around the Inferior Vena Cava after Radical Surgery of Undifferentiated Carcinoma of the Pancreatic Head Region]. Gan To Kagaku Ryoho. 2018; 45(2):359-361. View

19.

Katada T, Hashidate H, Yokoyama N, Sudo N, Mitsuma K, Otani T . Initial Features of Hepatic Metastases From Pancreatic Cancer: Histological and Radiolographical Appraisal of Hepatic Micrometastases Detected by Real-Time Fluorescent Imaging. Pancreas. 2017; 46(9):1196-1201. DOI: 10.1097/MPA.0000000000000915. View

20.

Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P . Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol. 2021; 45(6):101607. DOI: 10.1016/j.clinre.2020.101607. View